New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
oleh: Agostino Guida, Francesco Perri, Franco Ionna, Paolo A. Ascierto, Antonio M. Grimaldi
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-01-01 |
Deskripsi
Abstract Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.